Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
| Autor: | Hiroki Morita, Yui Yamasaki, Nobue Kojima, Masaru Miyashita, Houu Koh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Agonist
medicine.medical_specialty endocrine system medicine.drug_class Case Report Luteinizing hormone-releasing hormone agonist lcsh:Gynecology and obstetrics 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine medicine skin and connective tissue diseases lcsh:RG1-991 030219 obstetrics & reproductive medicine business.industry Ovarian hyperstimulation Obstetrics and Gynecology medicine.disease Long acting Endocrinology Estrogen 030220 oncology & carcinogenesis business Tamoxifen hormones hormone substitutes and hormone antagonists Hormone medicine.drug |
| Zdroj: | Case Reports in Obstetrics and Gynecology Case Reports in Obstetrics and Gynecology, Vol 2018 (2018) |
| ISSN: | 2090-6692 2090-6684 |
| Popis: | Tamoxifen treatment for breast cancer may induce ovarian cysts and supraphysiological levels of serum estrogen. We report successful management with luteinizing hormone-releasing hormone (LHRH) agonist of ovarian hyperstimulation induced by tamoxifen. A 49-year-old woman was operated on for invasive ductal carcinoma of the right breast. She received breast irradiation and adjuvant tamoxifen therapy. After 2 years, she had a cystic ovarian mass, and her serum concentration of estradiol was 1280 pg/mL. She was treated with an injection of 11.25 mg leuprolide acetate, a long-acting LHRH agonist, without abandoning tamoxifen therapy. The levels of estradiol decreased to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text